# Taiwan approves Lunit AI Solution for breast cancer detection

26 August 2022 | News

**Lunit's latest commercial approval to accelerate expansion in the Taiwanese market**

South Korea-based startup Lunit has received commercial approval in Taiwan for Lunit INSIGHT MMG, the company's artificial intelligent (AI) solution for mammography analysis. Recently, the Taiwan Food and Drug Administration (TFDA) issued a class 2 medical device license for Lunit's AI breast cancer detection solution.

Lunit INSIGHT MMG is one of the company's most mature radiology products, analyzing mammography images with high speed and 96% accuracy. By detecting suspicious lesions in mammography images, the AI solution helps radiologists distinguish suspected tumor areas by providing the location of the lesion with an abnormality score reflecting the AI's confidence level.

Following approvals by the U.S. FDA last year and Health Canada in June, Lunit's commercial approval in Taiwan signals the company's plans to actively expand in the Taiwanese medical device market.

"We started using Lunit INSIGHT MMG to speed up mammography interpretation and to reduce errors," said DrYeh Wei Cheng, director of the Department of Radiology, Nantou Hospital. "Lunit's AI tool is particularly effective in helping diagnose dense breasts, which are often more likely to be misdiagnosed among East Asian women, and has helped improve communication between radiologists and breast surgeons."